$257.13 0.3 0.1%
Last Trade - 16/04/21
| Market Cap | £69.97bn |
| Enterprise Value | £77.90bn |
| Revenue | £10.38bn |
| Position in Universe | 133rd / 6850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 9,946 | 11,325 | 12,444 | 13,601 | 14,884 | 14,351 | 17,091 | 18,331 | +7.6% | ||
| +89.4 | +13.4 | +13.8 | +80.3 | -35.8 | -11.0 | +47.1 | +13.0 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. Its segments include Orthopaedics, MedSurg, Neurotechnology and Spine. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. Its products include implants, which are used in joint replacement and trauma surgeries, and other products. It offers musculoskeletal care and sensor technology for total joint replacement.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | February 20, 1946 |
| Public Since | July 24, 1997 |
| No. of Shareholders: | 2,582 |
| No. of Employees: | 43,000 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 376,324,529 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 2825 Airview Blvd, PORTAGE, 49002-1802, United States |
| Web | https://www.stryker.com/ |
| Phone | +1 269 3892600 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 16/04/21, shares in Stryker are trading at $257.13, giving the company a market capitalisation of £69.97bn. This share price information is delayed by 15 minutes.
Shares in Stryker are currently trading at $257.13 and the price has moved by 47.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Stryker price has moved by 1.39% over the past year.
Of the analysts with advisory recommendations for Stryker, there are there are currently 9 "buy" , 12 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Stryker is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Stryker is scheduled to issue upcoming financial results on the following dates:
The Stryker dividend yield is 1.14% based on the trailing twelve month period.
Last year, Stryker paid a total dividend of 2.93, and it currently has a trailing dividend yield of 1.14%. Looking ahead, Stryker has not announced an ex-dividend date yet and the next dividend pay date is 2021-04-30.
Stryker has yet to annouce their ex-dividend date and the next dividend pay date is 2021-04-30. The historic dividend yield on Stryker shares is currently 1.14%.
To buy shares in Stryker you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Stryker are currently trading at $257.13, giving the company a market capitalisation of £69.97bn.
Here are the trading details for Stryker:
Based on an overall assessment of its quality, value and momentum, Stryker is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Stryker are currently priced at $257.13. At that level they are trading at 1.56% premium to the analyst consensus target price of 0.00.
Analysts covering Stryker currently have a consensus Earnings Per Share (EPS) forecast of 9.073 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stryker. Over the past six months, the relative strength of its shares against the market has been -5.7%. At the current price of $257.13, shares in Stryker are trading at 16.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Stryker PE ratio based on its reported earnings over the past 12 months is 41.7. The shares are currently trading at $257.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Stryker's management team is headed by:
Here are the top five shareholders of Stryker based on the size of their shareholding:
